Literature DB >> 19859013

Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program.

Daniel C Payne1, Peter G Szilagyi, Mary Allen Staat, Kathryn M Edwards, Jon R Gentsch, Geoffrey A Weinberg, Caroline B Hall, Aaron T Curns, Haley Clayton, Marie R Griffin, Gerry Fairbrother, Umesh D Parashar.   

Abstract

BACKGROUND: Since 2006, we have conducted population-based surveillance for rotavirus disease in children seen in hospitals and emergency departments (EDs) in Monroe County, NY (Rochester), Hamilton County, OH (Cincinnati), and Davidson County, TN (Nashville).
METHODS: During the 2006 and 2007 rotavirus seasons, clinical information and stool specimens were obtained from county children who were <3 years presenting with diarrhea and/or vomiting to the hospital or ED of the only children's hospital in each county. Specimens were tested for rotavirus and genotyped, and rates of hospitalization and ED visits were calculated.
RESULTS: While aggregate rotavirus hospitalization rates for the 3 sites were similar in 2006 and 2007 (22.5/10,000 and 26.8/10,000, respectively), individual rates for the 3 counties differed considerably. The rotavirus hospitalization rate in Rochester between 2006 and 2007 increased 3-fold, but decreased by 33% in Cincinnati and 41% in Nashville over the 2 study years. G1 strains accounted for >80% of strains at all 3 sites in 2006. However, in 2007, the uncommon P[8], G12 strain was detected in 69% of Rochester specimens, while the P[8], G1 strain remained predominant in the other 2 sites. No subjects received rotavirus vaccine in 2006 and coverage with 2 to 3 vaccine doses reached 15% in all 3 communities by June 2007.
CONCLUSIONS: During the 2006 and 2007 rotavirus seasons, with only limited vaccine use, remarkable variability was observed in the population-based rates of severe rotavirus and in the rotavirus serotypes across the 3 sites. This natural secular variability in rotavirus disease must be considered in the assessment of the impact of vaccine on disease rates and rotavirus serotypes.

Entities:  

Mesh:

Year:  2009        PMID: 19859013     DOI: 10.1097/INF.0b013e3181a6ad6e

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  30 in total

Review 1.  Rotavirus diversity and evolution in the post-vaccine world.

Authors:  John T Patton
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

2.  Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.

Authors:  Stephanie Donauer; Daniel C Payne; Kathryn M Edwards; Peter G Szilagyi; Richard W Hornung; Geoffrey A Weinberg; James Chappell; Caroline B Hall; Umesh D Parashar; Mary Allen Staat
Journal:  Vaccine       Date:  2013-04-12       Impact factor: 3.641

3.  Emergence of Rotavirus G12P[8] in St. Louis During the 2012-2013 Rotavirus Season.

Authors:  Kristine M Wylie; George M Weinstock; Gregory A Storch
Journal:  J Pediatric Infect Dis Soc       Date:  2014-09-15       Impact factor: 3.164

Review 4.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

5.  Decline in Emergency Department Visits for Acute Gastroenteritis Among Children in 10 US States After Implementation of Rotavirus Vaccination, 2003 to 2013.

Authors:  Minesh P Shah; Jacqueline E Tate; Claudia A Steiner; Umesh D Parashar
Journal:  Pediatr Infect Dis J       Date:  2016-07       Impact factor: 2.129

6.  Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.

Authors:  Daniel C Payne; Julie A Boom; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Eileen J Klein; Rangaraj Selvarangan; Parvin H Azimi; Christopher Harrison; Mary Moffatt; Samantha H Johnston; Leila C Sahni; Carol J Baker; Marcia A Rench; Stephanie Donauer; Monica McNeal; James Chappell; Geoffrey A Weinberg; Azadeh Tasslimi; Jacqueline E Tate; Mary Wikswo; Aaron T Curns; Iddrisu Sulemana; Slavica Mijatovic-Rustempasic; Mathew D Esona; Michael D Bowen; Jon R Gentsch; Umesh D Parashar
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

7.  Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: footprints of a globally transitioning genotype.

Authors:  Allison F Dennis; Sarah M McDonald; Daniel C Payne; Slavica Mijatovic-Rustempasic; Mathew D Esona; Kathryn M Edwards; James D Chappell; John T Patton
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

8.  Rotavirus infections in Detroit, USA, a region of low vaccine prevalence.

Authors:  Nahed Abdel-Haq; Muhammad Amjad; Eric McGrath; Hossein Salimnia; Marilynn Fairfax; Basim I Asmar
Journal:  Virusdisease       Date:  2016-03-22

9.  Impact of rotavirus vaccine on premature infants.

Authors:  Jean-Michel Roué; Emmanuel Nowak; Grégoire Le Gal; Thomas Lemaitre; Emmanuel Oger; Elise Poulhazan; Jean-Dominique Giroux; Armelle Garenne; Arnaud Gagneur
Journal:  Clin Vaccine Immunol       Date:  2014-07-30

10.  One year survey of human rotavirus strains suggests the emergence of genotype G12 in Cameroon.

Authors:  Valentine N Ndze; Hajnalka Papp; Eric A Achidi; Kamga H Gonsu; Brigitta László; Szilvia Farkas; Péter Kisfali; Béla Melegh; Mathew D Esona; Michael D Bowen; K Bányai; Jon R Gentsch; Abena M T Odama
Journal:  J Med Virol       Date:  2013-08       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.